Revvity, Inc. RVTY
NYSE · Healthcare · Medical - Diagnostics & Research
$145.22
Close on Fri, 20 Nov 2026 · market value $16.2B
What the price is betting on
Priced for a lot to go rightAt $145, the price assumes revenue grows about 12% a year for five years, from $2.9B to about $4.8B by FY2030. That is about three times what analysts expect for the next two years and about five times the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 9.3% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than RVTY? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$86
Base
$95
Bull
$106
Today $145
- Bear $86. Cash flow grows 2% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $95. Cash flow grows 4% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $106. Cash flow grows 6% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$3B$2.9B, below the path
- FY2027$3.4B$3B, below the path
- FY2028$3.8B$3.2B, below the path
- FY2029$4.3B$3.4B, below the path
- FY2030$4.8B$3.6B, below the path
Each year's revenue at 12% growth from $2.9B in the 12 months to October 2026.
At a glance
Healthcare · Medical - Diagnostics & Research · listed on NYSE
- Revenue, FY2025
- $2.9B
- Growth, 3 years a year
- 2.5%
- Cash margin
- 18%
- Net debt
- $2.6B
- Shares, 3-year change
- −3%
- Dividend yield
- 0.2%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.